- Conditions
- Non-Hodgkin's Lymphoma, Leukemia, Multiple Myeloma, Acute Myeloid Leukemia, Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndrome
- Interventions
- Thymoglobulin, Total-Body Irradiation, Allogeneic PBSCT or BMT, Tacrolimus, Mycophenolate Mofetil
- Biological · Radiation · Procedure + 1 more
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 40 Years to 70 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2017
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 489
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Acute Leukaemia, Chronic Disease, Leukemia, Myelodysplasia, Lymphoma
- Interventions
- Busulfan, Anti-Thymocyte Globulin, Fludarabine, Cyclosporine, Mycophenolate mofetil
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Chronic Myeloid Leukemia (CML), Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS), Juvenile Myelomonocytic Leukemia (JMML), Acute Lymphoblastic Leukemia (ALL), Lymphoma (Hodgkin's and Non-Hodgkin's)
- Interventions
- CliniMACS CD34+ Reagent System, Thiotepa, Cyclophosphamide, Alemtuzumab, Tacrolimus, Melphalan, Busulfan, Fludarabine, Methylprednisolone
- Device · Drug
- Lead sponsor
- Diane George
- Other
- Eligibility
- Up to 22 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Osteodysplasia
- Interventions
- Marrow stromal cell infusion
- Biological
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Not listed
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2008
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Leukemia, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Myeloproliferative Diseases, Non-Hodgkins Lymphoma, Hodgkins Lymphoma, Multiple Myeloma, Myelodysplastic Syndrome
- Interventions
- Fludarabine monophosphate, Busulfan, Stem Cell Infusion, Tacrolimus, Methotrexate, G-CSF
- Drug · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 5 Years to 75 Years
- Enrollment
- 201 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2022
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Psychosocial Effects of Cancer and Its Treatment
- Interventions
- psychosocial assessment and care
- Procedure
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2017
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Leukemia, Myelodysplastic Syndromes
- Interventions
- aldesleukin, therapeutic allogeneic lymphocytes, therapeutic autologous lymphocytes, cytarabine, etoposide, mitoxantrone hydrochloride, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 14 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Leukemia, Lymphoma
- Interventions
- Natural Killer (NK) Cell Infusion, Stem Cell Infusion
- Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 4 Years to 35 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2018
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Aplastic Anemia
- Interventions
- cyclophosphamide, anti-thymocyte globulin, cyclosporine, allogeneic bone marrow transplantation, methotrexate, DNA analysis, flow cytometry, polymorphism analysis, laboratory biomarker analysis
- Drug · Biological · Procedure + 2 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Up to 65 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 3
- States / cities
- Salt Lake City, Utah • Seattle, Washington • Milwaukee, Wisconsin
- Conditions
- Bone Marrow Failure, Osteopetrosis, Fanconi Anemia, Severe Combined Immunodeficiency
- Interventions
- Fludarabine, Cyclophosphamide, Busulfan, Alemtuzumab, Rabbit Anti-thymocyte Globulin, Horse Anti-thymocyte Globulin
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- Up to 30 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2021
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Interventions
- cyclosporine ophthalmic emulsion, placebo
- Drug · Other
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 5
- States / cities
- Palo Alto, California • Chicago, Illinois • Nashville, Tennessee + 2 more
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic/Myeloproliferative Diseases
- Interventions
- cyclophosphamide, cyclosporine, fludarabine phosphate, methylprednisolone, therapeutic allogeneic lymphocytes, thiotepa, allogeneic bone marrow transplantation, biological therapy, bone marrow ablation with stem cell support, bone marrow transplantation, chemotherapy, leukocyte therapy, non-specific immune-modulator therapy, peripheral blood lymphocyte therapy, peripheral blood stem cell transplantation, radiation therapy
- Drug · Procedure
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 10 Years to 50 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2007
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Leukemia
- Interventions
- cyclophosphamide, etoposide, allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, intensity-modulated radiation therapy, tomotherapy
- Drug · Procedure · Radiation
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 7 Years to 55 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2026
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Neutropenia, Sickle Cell Anemia, Thalassemia Major, Red-Cell Aplasia, Pure
- Interventions
- anti-thymocyte globulin, busulfan, cyclophosphamide, Bone marrow transplantation
- Drug · Procedure
- Lead sponsor
- Fairview University Medical Center
- Other
- Eligibility
- 0 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
- Interventions
- anti-thymocyte globulin, filgrastim, cyclophosphamide, fludarabine phosphate, methylprednisolone, tacrolimus, allogeneic bone marrow transplantation, in vitro-treated bone marrow transplantation, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Chimeric Therapies
- Industry
- Eligibility
- 12 Years to 50 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2003
- U.S. locations
- 15
- States / cities
- La Jolla, California • Denver, Colorado • Washington D.C., District of Columbia + 12 more
- Conditions
- Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Acute Myelogenous Leukemia, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Myelodysplastic Syndrome
- Interventions
- VCL-CB01, Phosphate-buffered Saline (PBS)
- Biological · Other
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 22
- States / cities
- Tucson, Arizona • Duarte, California • Denver, Colorado + 17 more
- Conditions
- Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid Cell Neoplasm, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts
- Interventions
- Dilanubicel, Cyclophosphamide, Fludarabine, Thiotepa, Total-Body Irradiation, Umbilical Cord Blood Transplantation, Laboratory Biomarker Analysis, Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy, Multigated Acquisition Scan, Electrocardiography, Computed Tomography
- Biological · Drug · Radiation + 2 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 10 Years to 65 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Renal Dysfunction, Acute Renal Failure, Mortality
- Interventions
- URODILATIN (ULARITIDE, ATRIAL NATRIURETIC PEPTIDE), MANNITOL
- Drug
- Lead sponsor
- Rocky Mountain Cancer Centers
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm
- Interventions
- Allogeneic Bone Marrow Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, Anti-Thymocyte Globulin, Bendamustine Hydrochloride, Fludarabine Phosphate, Inotuzumab Ozogamicin, Methotrexate, Peripheral Blood Stem Cell Transplantation, Rituximab, Tacrolimus
- Procedure · Biological · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Leukemia
- Interventions
- Clofarabine
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Lymphocytic Neoplasm, Lymphoma
- Interventions
- Allogeneic Bone Marrow Transplantation, Bendamustine, Filgrastim-sndz, Fludarabine, Inotuzumab Ozogamicin, Melphalan, Peripheral Blood Stem Cell Transplantation, Rituximab, Tacrolimus
- Procedure · Drug · Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Hematologic Malignancies, Nonmalignant Diseases, Immunodeficiencies, Hemoglobinopathies, Genetic Inborn Errors of Metabolism, Fanconi Anemia, Thalassemia, Sickle Cell Disease
- Interventions
- Fludarabine
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- Up to 17 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Graft Versus Host Disease
- Interventions
- D-SQUAME Skin Sampling Discs
- Device
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 3 Months to 30 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Lymphoma, Non-Hodgkin, Leukemia, Blood and Marrow Transplant (BMT), Lymphomas: Non-Hodgkin
- Interventions
- ablative allogeneic hematopoietic cell transplantation
- Procedure
- Lead sponsor
- Stanford University
- Other
- Eligibility
- Up to 50 Years
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1989 – 2009
- U.S. locations
- 1
- States / cities
- Stanford, California